RxDoctor Payments DataLook up a doctor →

Elena Christofides, MD

Endocrinology, Diabetes & Metabolism · Columbus, OHNPI 1306893433

Payments from drug & device makers

$3,529,051in general payments, 2019–2025

Across 3,641 payments — averaging $969.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$590K
  • Eli Lilly$402K
  • Corcept Therapeutics$335K
  • Abbott$286K
  • AbbVie$250K
  • Amgen$229K
  • plus $1.4M from 54 others
$109,968in research payments, 2019–2025

Across 36 payments — averaging $3054.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$103K
  • Corcept Therapeutics$4K
  • Recordati_rare_diseases_inc.$3K

What the payments were for

  • Consulting fees$161,5167%
  • Speaking & faculty fees$1,846,46180%
  • Travel & lodging$241,21510%
  • Food & beverage$53,0292%
  • Education$1,3380%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC749$589,906
Eli Lilly38$402,349
Corcept Therapeutics399$335,114
Abbott58$286,036
AbbVie(2 entities)295$250,497
Amgen(2 entities)67$228,727
Novo Nordisk403$223,037
Bayer247$202,478
Recordati_rare_diseases_inc.183$158,312
Xeris Pharmaceuticals, Inc.203$156,527
Ascendis Pharma Endocrinology Inc174$126,672
Amryt Pharma Holdings Ltd127$120,896
Sanofi US Services Inc.21$115,395
Boehringer Ingelheim148$114,056
AstraZeneca(2 entities)100$57,540
Chiesi USA, Inc.41$45,677
Chiasma, Inc.14$15,715
Shire North American Group Inc25$15,401
Alfasigma USA, Inc.10$13,553
Gilead2$12,142
Merck40$10,330
Ortho-clinical Diagnostics, Inc.2$9,180
Sanofi-aventis U.S. LLC20$9,157
Mannkind Corporation13$5,893
Madrigal Pharmaceuticals12$5,818
Medicure Pharma Inc.4$4,511
Zealand Pharma US, Inc.11$3,117
Pfizer33$2,531
Strongbridge US Inc.1$1,800
Janssen Research & Development, LLC1$1,111
Dexcom, Inc.24$786
Ipsen Innovation1$675
Aegerion Pharmaceuticals, Inc.7$481
Merz North America, Inc.8$460
Radius Health, Inc.18$397
Novartis14$380
Axsome Therapeutics, Inc.14$378
Amarin Pharma, Inc.19$258
Kowa Pharmaceuticals America, Inc.15$232
Kyowa Kirin, Inc.9$167
Astellas Pharma US Inc5$162
Johnson & Johnson7$120
Endo Pharmaceuticals Inc.6$98
Tandem Diabetes Care, Inc.5$88
Cequr Corporation1$86
Jazz Pharmaceuticals Inc.1$85
Esperion Therapeutics, Inc.5$82
EUSA Pharma (US) LLC4$72
Valeritas, Inc.4$72
Sequel Med Tech, LLC3$58
Rhythm Pharmaceuticals, Inc.3$55
Clarus Therapeutics Inc.5$54
IBSA Pharma Inc.4$51
Antares Pharma, Inc.3$50
Neurocrine Biosciences, Inc.2$43
BETA Bionics, Inc.3$35
Currax Pharmaceuticals LLC3$33
Ascensia Diabetes Care US Inc.1$23
Sun Pharmaceutical Industries Inc.1$18
Bigfoot Biomedical Inc1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,529,051 in reported general payments places this provider in the 95th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

See all endocrinology, diabetes & metabolism providers in Ohio

Medicare billing

Part B allowed, 2024
$43,924
Medicare patients
101
Services billed
333

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RecorlevLevoketoconazole33$606,500
IsturisaOsilodrostat Phosphate39$567,470
GenotropinSomatropin33$121,436
OzempicSemaglutide88$107,074
MounjaroTirzepatide79$105,023
JardianceEmpagliflozin66$67,897
OmnitropeSomatropin26$58,951
TrulicityDulaglutide31$32,287
KerendiaFinerenone32$27,692
ProliaDenosumab11$19,145
SynthroidLevothyroxine Sodium126$12,849
Tresiba Flextouch U-100Insulin Degludec30$11,903
Tresiba Flextouch U-200Insulin Degludec17$11,484
Synjardy XrEmpagliflozin/Metformin Hcl12$6,705
Humulin R U-500 KwikpenInsulin Regular, Human12$5,615

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Xeris Pharmaceuticals, Inc.Recorlev$156,527$606,50033 claims
Recordati_rare_diseases_inc.Isturisa$158,312$567,47039 claims
Lilly USA, LLCMounjaro, Trulicity$589,906$137,310110 claims
PfizerGenotropin$2,531$121,43633 claims
Novo NordiskOzempic$223,037$107,07488 claims
Boehringer IngelheimJardiance, Synjardy Xr$114,056$74,60278 claims
BayerKerendia$202,478$27,69232 claims
AmgenProlia$228,727$19,14511 claims
AbbVieSynthroid$250,497$12,849126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.

Other endocrinology, diabetes & metabolism in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →